Stock Watch: Queasiness After The Humira Banquet
AbbVie Is Not The Only Company To Suffer
The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.
You may also be interested in...
Stock Watch: Novartis Earnings Get Interesting Boost
A number of facets from last quarter’s earnings season carried over to Novartis’s first-quarter report, including pipeline attrition and the dependence of sales growth on a single product. While new, still minor products are hoped eventually to buffer its patent expiries, help from another corner has emerged.
Amgen Falters In Core Immunology Business, But Help Is On The Horizon
Sales of Amgen’s key immunology drugs Otezla and Enbrel plunged in Q1, impacted by inventory and competition, but the company will add a new blockbuster when its Horizon acquisition closes in June.
Stock Watch: J&J’s Q1 Earnings Untroubled By The IRA
J&J’s Q1 earnings announcement included challenges like the loss of exclusivity and competitive pressures, but the price renegotiation associated with the Inflation Reduction Act was not among them.